Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Natera Inc. Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $103.58 (market cap $29.10B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 126 Days and Natera Inc. Common Stock for 0 Days on average.
| LQD | NTRA | |
|---|---|---|
Market Cap | $29.10B | $57.03B |
Volume | 33,185,388 | 1,131,157 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $425.64 |
52-Week Low | $101.83 | $179.42 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.55, showing minimal daily movement with a slight decline of -0.03%. The ETF faces bearish technical signals across multiple indicators while maintaining regular dividend distributions. Recent news highlights significant short interest growth of 53.1% in September 2026 and unusual options activity, reflecting heightened market uncertainty amid rising bond yields and geopolitical tensions affecting corporate debt markets.
The investment-grade corporate bond ETF faces headwinds from rising Treasury yields and increased borrowing costs for corporations. While the 4.8% yield provides income appeal, the bearish technical outlook and growing short interest suggest near-term pressure. Key risks include further Fed rate hikes and economic slowdown impacting corporate credit quality.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
